Biopharma: How do the tolerability profiles of the monthly GLP-1's compare?

Research evidence excerpt

Biopharma: How do the tolerability profiles of the monthly GLP-1's compare?

Idea

June 10, 2026 10:07 PM GMT

Morgan Stanley & Co. LLCMBiopharma | North America Terence C Flynn, Ph.D.

Equity Analyst

How do the tolerability profiles Terence.Flynn@morganstanley.comHailey Horowitz +1 212 761-2230

Research Associate

Hailey.Horowitz@morganstanley.com +1 212 761-5264

of the monthly GLP-1's Alexander Yevdokimov, Ph.D.

Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

compare? Chris Yu, J.D., Ph.D.

Chris.L.Yu@morganstanley.com +1 212 761-2535

Following additional Ph2 data for PFE's Berobentide (injectable Connor M Massari

weekly/monthly GLP-1) at ADA, we review the profile and EquityConnor.Massari@morganstanley.comAnalyst +1 212 761-2417

titration strategy relative to AMGN's MariTide (GLP-1/GIP) as Damien H Kerner

both drugs move into broad Ph3 development. ResearchDamien.H.Kerner@morganstanley.comAssociate +1 212 761-3829

As the obesity treatment landscape continues to evolve (see our ADA Morgan Stanley India Company Private Limited+

Saket Agarwal

conference recap HERE), differentiation among next-gen therapies remains a key Research Associate

focus. While first and second-gen GLP-based agents (Novo's Semaglutide and LLY's Saket.Agarwal@morganstanley.com +91 22 6995-4012

Tirzepatide) established the clinical efficacy of the class in obesity, the next wave of

development is focused on further improving efficacy (LLY's Retatrutide, a tri-

agonist), as well as enhancements in convenience and tolerability, which could

improve long-term persistence. One such axis of differentiation is extended dosing

intervals, with companies seeking to move beyond weekly injections toward

monthly or less-frequent administration schedules that could reduce treatment

burden.